Colorectal cancer patients treated with SIR-spheres more likely to be candidates for resection

Treatment with Sirtex Medical‘s (ASX:SRX) Y-90 resin microspheres and chemotherapy was associated with a statistically significant gain in potentially curative liver resectability, according to data published earlier this week.

The results come 1 week after the Australian company reported that its radioactive microspheres had no effect in improving survival in patients with colorectal cancer in its Foxfire analysis.

Get the full story at our sister site, Drug Delivery Business News.

The post Colorectal cancer patients treated with SIR-spheres more likely to be candidates for resection appeared first on MassDevice.

from MassDevice http://ift.tt/2rlGcgG